Jinshiya Pharmaceutical (300434.SZ) released its performance for the first half of the year, with a net profit attributable to the parent company of 65.7454 million yuan, an increase of 67.71%.

Wisdom Financial APP news, Jinshi Asia Medicine (300434.SZ) released its 2025 interim report. The company's operating income was 492 million yuan, a decrease of 5.80% year-on-year. Net profit attributable to shareholders of the listed company was 65.7454 million yuan, an increase of 67.71% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 55.723 million yuan, an increase of 50.45% year-on-year. Basic earnings per share were 0.1637 yuan.